Ocular Therapeutix Inc(OCUL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:00 AM ET (Korea 9/11 17:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.41 | Insider Own | 8.6% | Shs Outstand | 219.6M | Perf Week | -2.57% |
| Market Cap | 2.33B | Forward P/E | - | EPS next Y | 1.72% | Insider Trans | -0.39% | Shs Float | 200.7M | Perf Month | 8.81% |
| Enterprise Value | 1.81B | PEG | - | EPS next Q | -0.36 | Inst Own | 89.09% | Short Float | 14.21% | Perf Quarter | 21.51% |
| Income | -0.30B | P/S | 44.81 | EPS this Y | -5.36% | Inst Trans | -0.2% | Short Ratio | 10.72 | Perf Half Y | 11.79% |
| Sales | 0.05B | P/B | 4.48 | EPS next 5Y | 10.55% | ROA | -53.7% | Short Interest | 28.52M | Perf YTD | -12.52% |
| Book/sh | 2.37 | P/C | 3.9 | EPS past 3/5Y | -15.4% 11.13% | ROE | -72.99% | 52W High | -35.4% ($16.44) | Perf Year | -18.62% |
| Cash/sh | 2.73 | P/FCF | - | Sales past 3/5Y | 0.29% 24.45% | ROIC | -50.55% | 52W Low | 70.46% ($6.23) | Perf 3Y | 183.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -10.6% | Gross Margin | 87.11% | Volatility(W/M) | 5.64% 5.05% | Perf 5Y | -2.3% |
| Dividend TTM | - | EV/Sales | 34.83 | Sales Y/Y TTM | -8.14% | Oper. Margin | -603.04% | ATR (14) | 0.55 | Perf 10Y | 56.64% |
| Dividend Ex-Date | - | Quick Ratio | 13.03 | EPS Q/Q | 10.89% | Profit Margin | -579.1% | RSI (14) | 52.32 | Recom | 1.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.11 | Sales Q/Q | 0.12% | SMA20 | -1.67% ($10.8) | Beta | 0.94 | Target Price | $27.17 |
| Payout | - | Debt/Eq | 0.15 | Earnings | 2026/8/3 | SMA50 | 7.95% ($9.84) | Rel Volume | 0.9 | Prev Close | $11.47 |
| Employees | 325 | LT Debt/Eq | 0.15 | EPS/Sales Surpr. | 11.5% 2.07% | SMA200 | 6.86% ($9.94) | Avg Volume(3M) | 2.66M | Price | $10.62 |
| IPO | 2014/7/25 | Option/Short | Yes/Yes | Trades | 14220 | Volume | 2,389,797 | Change | -7.41% |
Company
OCUL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
👁️ This is a US biotech company that develops and commercializes therapeutics for ophthalmic (eye) diseases. Leveraging its proprietary drug delivery technology that enables the slow release of medications, the company develops treatments for eye disorders and holds a commercialized product along with late-stage clinical candidates targeting conditions such as age-related macular degeneration. It has established itself as an ophthalmic biotech player by combining its sustained drug-release technology with its eye care pipeline.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
OCUL has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -5.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +183.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 89.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PJP 0.03%
XPH 0.02%
PILL 0.01%
SURI 0.01%
XEUR 0.01%It ranks #4 in the industry
Based on market cap of $2B.
OCUL $2B PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is OCUL?
OCUL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OCUL?
The market cap of OCUL is approximately $2.3B, ranking 1,969 within its sector.
What is the 52-week high and low for OCUL?
OCUL has recorded a 52-week high of $16.44 and a low of $6.23.
